Search

Project seeks $6m injection

RENOWNED for its volatility worldwide, the biotechnology sector has again been enjoying a sustained pick-up over the past two months.

Local company Eastland Medical Systems is of the view that while the market remains tough, recent signs show the timing is right for new ventures.

The biotech sector has accounted for a significant proportion of recently announced market floats in the US and Eastland is also prepared to brave the times.

Eastland has announced an initial public offering, hoping to raise $6 million in time to list on the Australian Stock Exchange in January.

The company already has 70 per cent of the capital it needs to bring to market three retractable injection, infusion and blood-drawing devices, for which it has obtained exclusive production licences for Australasia.

The products are fully developed and contracts for outsourcing large-scale manufacturing are almost in place.

Eastland believes it has a strategic market advantage in that its add-on products are complementary to existing syringes and canulas.

The company is also convinced the products are more affordable, safer and easier to use than other products designed to prevent needlestick injuries.

Existing retractable syringes costing three times the value of the Eastland product have failed to prevent injury in some instances and are limited in application.

The company has welcomed Federal Government recognition and promised support for the introduction of safer products to prevent needle stick injury.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/03/18

1 year TSR5 year TSR
9thAdvance NanoTek1725%106%
184thGoldfields Money57%14%
409thWestStar Industrial3%-51%
642ndSUDA Pharmaceuticals-33%-15%
720thCarnegie Clean Energy-49%1%
716 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

11/12/17
$0 Issued
11/12/17
$0 Issued
11/12/17
$0 Issued
Total value as at the date of the transaction
Source: Morningstar

Revenue

92nd↓SUDA Pharmaceuticals$7.3m
96th↑Carnegie Clean Energy$5.3m
97th↓Advance NanoTek$5.1m
100th↑WestStar Industrial$4.6m
101st↓Goldfields Money$4.2m
236 listed industrial companies ranked by revenue.
Source: Morningstar

Remuneration from SUDA Pharmaceuticals

472ndStephen Carter$279k
477thJoseph Ohayon$277k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer